Date: November 1, 2021

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 mRNA Vaccine SPIKEVAX™ (Moderna)

- **Doses and Schedule:**
  The booster dose has been revised to indicate that a full dose (0.5 mL [100 mcg]) should be used for residents of long term care (LTC), assisted living and independent living facilities, alternate level of care clients awaiting placement in LTC, and individuals 70 years of age and older. A half dose (0.25 mL [50 mcg]) should be used for all other eligible individuals recommended to receive a booster dose.

- **Booster Doses:**
  For all eligible individuals, the minimum age for which a booster dose is recommended has been revised from ‘12 years of age and older’ to ‘18 years of age and older’. This includes individuals who will be turning 18 years of age within the current calendar year.

These recommendations align with the NACI Interim guidance on booster COVID-19 vaccine doses in Canada, U.S. Food and Drug Administration (FDA) authorization of a 0.25 mL dose for booster dose indications for this product, and is in keeping with US CDC guidance and expected Health Canada authorization.

Please remove page numbers: 1-5 dated October 29, 2021
Please add new page numbers: 1-5 dated November 1, 2021

COVID-19 mRNA Vaccine COMIRNATY™ (Pfizer-BioNTech)

- **Booster Doses:**
  For all eligible individuals, the minimum age for which a booster dose is recommended has been revised from ‘12 years of age and older’ to ‘18 years of age and older’. This includes individuals who will be turning 18 years of age within the current calendar year.
COVID-19 Vaccine VAXZEVRIA™/COVISHIELD (AstraZeneca/Verity Pharmaceuticals)

- Booster Doses:
  For all eligible individuals, the minimum age for which a booster dose is recommended has been revised from ‘12 years of age and older’ to ‘18 years of age and older’. This includes individuals who will be turning 18 years of age within the current calendar year.

COVID-19 Vaccine (Ad26.COV2.S [recombinant]) (Janssen Inc.)

- Booster Doses:
  For all eligible individuals, the minimum age for which a booster dose is recommended has been revised from ‘12 years of age and older’ to ‘18 years of age and older’. This includes individuals who will be turning 18 years of age within the current calendar year.
If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCP FACP M
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:
Provincial Health Officer
Dr. Bonnie Henry

Dr. Reka Gustafson
Vice President, Public Health & Wellness, PHSA & Deputy Provincial Health Officer

Deputy Provincial Health Officer
Dr. Martin Lavoie

BC Ministry of Health, Population & Public Health Division:

Brian Sagar
Senior Director Communicable Disease, Population and Public Health Division

Bernard Achampong
Executive Director, Public Health, Planning and Prevention, Population and Public Health Division